<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="35664">Statins</z:chebi> exert beneficial effects in <z:e sem="disease" ids="C0006111" disease_type="Disease or Syndrome" abbrv="">brain diseases</z:e> including <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Here, we investigated whether oral prophylactic <z:chebi fb="0" ids="39548">atorvastatin</z:chebi> provides long-term neuroprotection and functional recovery in permanent middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (pMCAO), and whether cerebral hemodynamics are affected </plain></SENT>
<SENT sid="2" pm="."><plain>Male Long-Evans rats were treated with 10 mg/kg oral <z:chebi fb="0" ids="39548">atorvastatin</z:chebi> for 14 days and subjected to pMCAO </plain></SENT>
<SENT sid="3" pm="."><plain>Cerebral hemodynamics were measured by bolus tracking MRI and laser Doppler flowmetry (LDF) </plain></SENT>
<SENT sid="4" pm="."><plain><z:mpath ids='MPATH_124'>Infarct</z:mpath> volume was quantified at 1 week by T2-MRI and at 3 weeks by histology </plain></SENT>
<SENT sid="5" pm="."><plain>Rats were also subjected to neuroscoring and cylinder test </plain></SENT>
<SENT sid="6" pm="."><plain>The number of animals per group was 10 </plain></SENT>
<SENT sid="7" pm="."><plain>The <z:mpath ids='MPATH_124'>infarct</z:mpath> volumes were 100.8 +/- 8.2 and 47.3 +/- 5.5 mm(3) in vehicle, and 68.7 +/- 11.0 and 28.6 +/- 3.82 mm(3) in <z:chebi fb="0" ids="39548">atorvastatin</z:chebi> group at 7 and 21 days post-<z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, respectively (mean +/- <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SEM</z:e>) </plain></SENT>
<SENT sid="8" pm="."><plain><z:chebi fb="0" ids="39548">Atorvastatin</z:chebi> significantly reduced <z:mpath ids='MPATH_124'>infarct</z:mpath> volume both at 7 and 21 days (P = 0.04 and 0.03, respectively, 1-way ANOVA) </plain></SENT>
<SENT sid="9" pm="."><plain>Interestingly, no improvement in cerebral hemodynamic parameters was observed in <z:chebi fb="0" ids="39548">atorvastatin</z:chebi> treated animals </plain></SENT>
<SENT sid="10" pm="."><plain>The vehicle group recovered <z:mpath ids='MPATH_458'>normal</z:mpath> neuroscore at day 13, whereas <z:chebi fb="0" ids="39548">atorvastatin</z:chebi> group recovered already at day 10 after pMCAO </plain></SENT>
<SENT sid="11" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> treatment groups preferred to use the unaffected forelimb for rearing in Cylinder test, whereas the defected forelimb use was minimal in <z:hpo ids='HP_0000001'>all</z:hpo> groups </plain></SENT>
<SENT sid="12" pm="."><plain>These results suggest that oral <z:chebi fb="0" ids="39548">atorvastatin</z:chebi> protects cerebral tissue against the subsequent pMCAO without influencing cerebral hemodynamic parameters, and it may well be that persons with ongoing <z:chebi fb="0" ids="39548">atorvastatin</z:chebi> treatment benefit in the incidence of <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
</text></document>